drugset / Trial / NCT07385703
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 3
Recruiting
752 enrolled
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment
Summary
This study primarily evaluates the efficacy and safety of the LM-302 plus tislelizumab regimen versus tislelizumab plus chemotherapy in the treatment of previously untreated locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma patients with CLDN18.2 positivity.
Timeline
- Start
- 2026-04-15
- Primary completion
- 2028-10
- Completion
- 2030-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | — | — |
| Comparator | Oxaliplatin | Small molecule | — | — |
| Subject | TPX4589 | Other / unclassified | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |